- Home
- CURV vs GNLX Comparison
CURV vs GNLX Comparison
Compare CURV & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CURV | GNLX |
|---|---|---|
| Founded | 2001 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Clothing/Shoe/Accessory Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 159.2M | 133.0M |
| IPO Year | 2021 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CURV | GNLX |
|---|---|---|
| Price | $2.10 | $2.85 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $1.59 | ★ $17.25 |
| AVG Volume (30 Days) | ★ 555.9K | 165.9K |
| Earning Date | 06-04-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 9.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,000,092,000.00 | $8,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.15 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.94 | $2.29 |
| 52 Week High | $3.14 | $8.54 |
Technical Indicators
Market Signals| Indicator | CURV | GNLX |
|---|---|---|
| Relative Strength Index (RSI) | 64.25 | 46.46 |
| Support Level | $1.03 | $2.33 |
| Resistance Level | $2.23 | $2.97 |
| Average True Range (ATR) | 0.21 | 0.18 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 93.63 | 39.58 |
Price Performance
Historical ComparisonAbout CURV Torrid Holdings Inc.
Torrid Holdings Inc is a direct-to-consumer brand in North America dedicated to offering a diverse assortment of stylish apparel, intimates, and accessories skillfully designed for curvy women. Its extensive collection features high-quality merchandise, including tops, bottoms, denim, dresses, intimates, activewear, footwear, and accessories. The company has one reportable segment, which includes the operation of its e-Commerce platform and stores.
About GNLX Genelux Corporation
Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.